Beijing Wantai Biological Pharmacy Enterprise Co Ltd (603392) - Total Assets
Based on the latest financial reports, Beijing Wantai Biological Pharmacy Enterprise Co Ltd (603392) holds total assets worth CN¥13.76 Billion CNY (≈ $2.01 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Beijing Wantai Biological Pharmacy Enter (603392) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd - Total Assets Trend (2013–2025)
This chart illustrates how Beijing Wantai Biological Pharmacy Enterprise Co Ltd's total assets have evolved over time, based on quarterly financial data. Check Beijing Wantai Biological Pharmacy Enter cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Beijing Wantai Biological Pharmacy Enterprise Co Ltd's total assets of CN¥13.76 Billion consist of 53.6% current assets and 46.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 17.3% |
| Accounts Receivable | CN¥1.62 Billion | 11.5% |
| Inventory | CN¥702.08 Million | 5.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥962.96 Million | 6.9% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Beijing Wantai Biological Pharmacy Enterprise Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Beijing Wantai Biological Pharmacy Enter (603392) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Beijing Wantai Biological Pharmacy Enterprise Co Ltd's current assets represent 53.6% of total assets in 2025, a decrease from 59.9% in 2013.
- Cash Position: Cash and equivalents constituted 17.3% of total assets in 2025, down from 22.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, a decrease from 9.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 11.5% of total assets.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd Competitors by Total Assets
Key competitors of Beijing Wantai Biological Pharmacy Enterprise Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Nanobiotix S.A
PA:NANO
|
France | €45.17 Million |
Beijing Wantai Biological Pharmacy Enterprise Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.21 | 4.14 | 2.30 |
| Quick Ratio | 3.73 | 3.62 | 1.84 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥5.13 Billion | CN¥5.78 Billion | CN¥1.43 Billion |
Beijing Wantai Biological Pharmacy Enterprise Co Ltd - Advanced Valuation Insights
This section examines the relationship between Beijing Wantai Biological Pharmacy Enterprise Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.33 |
| Latest Market Cap to Assets Ratio | 0.36 |
| Asset Growth Rate (YoY) | -4.4% |
| Total Assets | CN¥14.04 Billion |
| Market Capitalization | $5.08 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Beijing Wantai Biological Pharmacy Enterprise Co Ltd's assets below their book value (0.36x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Beijing Wantai Biological Pharmacy Enterprise Co Ltd's assets decreased by 4.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Beijing Wantai Biological Pharmacy Enterprise Co Ltd (2013–2025)
The table below shows the annual total assets of Beijing Wantai Biological Pharmacy Enterprise Co Ltd from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥14.04 Billion ≈ $2.06 Billion |
-4.39% |
| 2024-12-31 | CN¥14.69 Billion ≈ $2.15 Billion |
-6.53% |
| 2023-12-31 | CN¥15.71 Billion ≈ $2.30 Billion |
-3.17% |
| 2022-12-31 | CN¥16.23 Billion ≈ $2.37 Billion |
+130.34% |
| 2021-12-31 | CN¥7.05 Billion ≈ $1.03 Billion |
+101.10% |
| 2020-12-31 | CN¥3.50 Billion ≈ $512.70 Million |
+61.84% |
| 2019-12-31 | CN¥2.16 Billion ≈ $316.80 Million |
+19.30% |
| 2018-12-31 | CN¥1.81 Billion ≈ $265.54 Million |
+9.60% |
| 2017-12-31 | CN¥1.66 Billion ≈ $242.29 Million |
+13.84% |
| 2016-12-31 | CN¥1.45 Billion ≈ $212.83 Million |
+32.03% |
| 2015-12-31 | CN¥1.10 Billion ≈ $161.20 Million |
+36.76% |
| 2014-12-31 | CN¥805.50 Million ≈ $117.87 Million |
+32.71% |
| 2013-12-31 | CN¥606.98 Million ≈ $88.82 Million |
-- |
About Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. research, develops, produces, and sells biological diagnostic tests and vaccines in China and internationally. The company offers in vitro diagnostics and automated laboratory instruments, including Wan600, Wan BC2800, WanTLA immunoassay and biochemistry analyzers; chemiluminescence and biochemistry tests, including novel diagnostic tests fo… Read more